Adjuvant Chemotherapy in Combination With Tislelizumab in Lymph Node-Positive Esophageal Squamous Cell Carcinoma

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 2, 2023

Primary Completion Date

June 30, 2025

Study Completion Date

June 30, 2029

Conditions

Esophageal Squamous Cell Carcinoma

Interventions

DRUG

Tislelizumab

Adjuvant Chemotherapy （nab-paclitaxel 260mg/m2 d1 plus Cisplatin 75mg/m2 d1 or 25mg/m2 d1-3) in combination with Tislelizumab (200 mg Q3W)

Trial Locations (1)

RECRUITING

Cancer Hospital of Shantou University Medical College, Shantou

All Listed Sponsors

lead

Affiliated Cancer Hospital of Shantou University Medical College

OTHER